For C. diff, Gut Specialists Now Favor the Narrower Antibiotic

CATEGORY: GUT & DIGESTIVE HEALTH

A course of antibiotics is supposed to end an illness, not start one. Yet for more than 360,000 Americans a year, antibiotics open the door to Clostridioides difficile, or C. diff, a gut infection that brings relentless watery diarrhea and a frustrating habit of coming back.¹ New guidance from the American Gastroenterological Association now favors fidaxomicin, a narrower antibiotic, over the longtime standard vancomycin for most infections, because fewer infections return after it. After a second recurrence, the advice is to restore the gut’s own bacteria with stool-based therapy. Probiotics didn’t make the cut.

Fourteen Pieces of Advice, and the Thinking Behind Them

This isn’t a single trial. It’s a set of fourteen best practice statements from the gastroenterologists’ professional body, published this summer in Clinical Gastroenterology and Hepatology, resting on randomized drug trials and the evidence reviews behind earlier guidelines.¹ The logic running through all fourteen starts with how C. diff takes hold. Your intestines normally house a dense community of resident bacteria that crowds out troublemakers. A broad antibiotic clears that ground the way a plow clears a field, and C. diff is the weed that moves in first. That’s why the update leans toward treatments that spare or rebuild the gut’s normal residents instead of flattening them again.

Why the Narrower Drug Comes First

For most infections, the update favors fidaxomicin, an antibiotic that targets C. diff while leaving more of the surrounding gut bacteria alive. Fewer patients relapse after it than after vancomycin. Vancomycin remains an acceptable choice for reasons of cost and availability, and metronidazole is reserved for the most dangerous, fulminant form of the illness. Two older habits get retired. Routine retesting after treatment is out, since the test can stay positive long after the infection is gone. And taking vancomycin preventively during a later course of antibiotics is advised against.

When It Comes Back, Rebuild Rather Than Re-Treat

Recurrence is the heart of this disease. A first comeback gets a tapering course of vancomycin or fidaxomicin. After a second one, the update says to offer a fecal transplant or one of the newer approved microbiota products, which restore a healthy community of gut bacteria from a screened donor. That echoes the association’s 2024 guideline, which reached the same conclusion for people with repeated infections.² For those at high risk, the option can come even earlier. Store-bought probiotics, by contrast, aren’t advised for preventing C. diff at all. What does get encouraged is ordinary food: a high-fiber diet with a wide variety of fruits and vegetables, which feeds the protective bacteria. Two more facts worth having. Spread to healthy family members at home is uncommon. And the clearest protection of all is skipping antibiotics you don’t truly need.

Key Takeaways

• Gastroenterologists now favor fidaxomicin over vancomycin for most C. diff infections, mainly because fewer infections come back after it.
• After a second recurrence, the recommended move is restoring the gut’s bacteria with a fecal transplant or an approved microbiota product, not another ordinary antibiotic course alone.
• Probiotics aren’t advised for preventing C. diff, and neither is preventive vancomycin during other antibiotic treatment; a varied, high-fiber diet is encouraged instead.
• Household spread is uncommon, and avoiding unnecessary antibiotics remains the strongest protection against the infection in the first place.

References

1. Fischer M, et al. AGA Clinical Practice Update on Management of Clostridioides difficile Infection in Adults: Expert Review. Clinical Gastroenterology and Hepatology. 2026;24:2359–2369. link
2. Peery AF, Kelly CR, Kao D, et al. AGA Clinical Practice Guideline on Fecal Microbiota–Based Therapies for Select Gastrointestinal Diseases. Gastroenterology. 2024;166(3):409–434. link